Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study
Monte Rosa Therapeutics announced positive results from its Phase I GFORCE-1 study of MRT-8102, showing significant NEK7 degradation and reductions in inflammatory biomarkers with a safety profile comparable to placebo. The company plans to advance MRT-8102 into a Phase IIb cardiovascular study (GFORCE-2) in early 2027, along with Phase II trials for gout and hidradenitis suppurativa. While biomarker data are promising, further studies are needed to confirm the impact on major adverse cardiovascular events.
HC Wainwright & Co. reiterates Buy rating on Monte Rosa Therapeutics, $25 price target
HC Wainwright & Co. has reiterated a Buy rating for Monte Rosa Therapeutics (GLUE) with a price target of $25.00, suggesting a significant upside of 138.1% from its recent closing price. This positive outlook is supported by the company's strong pipeline of clinical programs targeting immune-mediated diseases and metastatic prostate cancer, and a robust probability-adjusted valuation of approximately $2.9 billion.
Brokers Set Expectations for GLUE Q3 Earnings
HC Wainwright anticipates Monte Rosa Therapeutics (NASDAQ:GLUE) to report a Q3 2026 loss of $0.45 per share, maintaining a "Strong Buy" rating despite the company missing previous earnings and revenue expectations. Analysts generally hold a "Moderate Buy" consensus with an average price target of $28, significantly higher than its current share price of $10.50. The article highlights positive sentiment due to encouraging Phase 1 data for MRT-8102 and pipeline advancement, tempered by neutral sentiment regarding employee equity grants.
H.C. Wainwright Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25
H.C. Wainwright has initiated coverage on Monte Rosa Therapeutics (GLUE.US) with a Buy rating. The firm has set a price target of $25 for the company's stock. This indicates a positive outlook from the analyst firm regarding Monte Rosa Therapeutics' future performance.
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Raised to "Strong-Buy" at HC Wainwright
HC Wainwright has upgraded Monte Rosa Therapeutics (NASDAQ:GLUE) to a "strong-buy" rating. Despite this upgrade, GLUE shares recently fell 5.6% to $11.26, significantly below their 52-week high, and the company missed quarterly earnings and revenue estimates. The upgrade follows positive Phase 1 results for MRT-8102, showing sustained protein degradation and improved disease biomarkers without major safety concerns, though Phase 2 trials are needed to confirm clinical benefits.
Monte Rosa’s MRT-8102 shows NLRP3 inflammasome activity normalization in Phase 1 study
Monte Rosa Therapeutics announced positive Phase 1 data for its oral molecular glue degrader, MRT-8102, which showed normalization of key pathogenic drivers of atherosclerotic cardiovascular disease in obese participants. The drug targets NEK7, crucial for NLRP3 inflammasome assembly, and demonstrated significant NEK7 degradation and reductions in inflammatory markers without serious adverse events. This promising result paves the way for multiple planned Phase 2 trials for conditions like gout, coronary artery disease, and hidradenitis suppurativa.
Monte Rosa Therapeutics Shares Surge Premarket - Monte Rosa Therapeutics (NASDAQ:GLUE)
Monte Rosa Therapeutics (NASDAQ:GLUE) shares surged over 20% in pre-market trading, driven by anticipation of expanded Phase 1 data for its experimental cardiovascular drug, MRT-8102. The biotech company is set to host a conference call to discuss results from the GFORCE-1 Phase 1 study, which evaluates MRT-8102 as a NEK7-directed molecular glue degrader for patients with elevated cardiovascular disease risk. Investors are keen to see the safety and activity data from multiple dose levels, as well as pioneering data on the drug's modulation of atherosclerotic cardiovascular disease drivers.
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics announced positive Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, which demonstrated significant reductions in inflammatory biomarkers related to cardiovascular disease. The company plans to advance MRT-8102 into three Phase 2 studies for gout, stable coronary artery disease, and hidradenitis suppurativa, with initial data for the gout study expected in late 2027. Despite the positive news, shares of Monte Rosa Therapeutics (NASDAQ: GLUE) were down on the day of the announcement.
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Monte Rosa Therapeutics announced positive results from its GFORCE-1 Phase 1 study for MRT-8102, a NEK7-directed molecular glue degrader. The study demonstrated that MRT-8102 normalized key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) in obese subjects with elevated CVD risk, showing robust NEK7 degradation and reduction of inflammatory biomarkers. Based on these findings, the company plans to advance MRT-8102 into Phase 2 trials for coronary artery disease, gout, and hidradenitis suppurativa.
Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial
Monte Rosa Therapeutics has announced positive Phase 1 results for its drug MRT-8102 in the GFORCE-1 trial, which is designed to treat inflammatory diseases. The study demonstrated significant NEK7 degradation and a reduction in lipoprotein(a) among obese participants, with no serious adverse events reported. Following these promising results, the company plans to advance MRT-8102 into three Phase 2 trials for coronary artery disease, gout, and hidradenitis suppurativa.
An experimental drug brought several heart-disease markers to levels seen in healthy volunteers
Monte Rosa Therapeutics announced positive Phase 1 results for its experimental drug MRT-8102, showing significant reductions in key inflammatory and cardiovascular disease markers in obese subjects with elevated CVD risk. The drug normalized several pathogenic drivers of ASCVD to levels comparable to healthy volunteers, with no serious adverse events. Monte Rosa plans to advance MRT-8102 into Phase 2 studies for coronary artery disease, gout, and hidradenitis suppurativa.
HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with Buy rating, $25 price target
HC Wainwright & Co. initiated coverage on Monte Rosa Therapeutics (GLUE) with a Buy rating and a $25 price target, suggesting a 109.6% upside. The analyst note highlighted strong early clinical data for MRT-8102, which showed an 85% median reduction in hsCRP levels, and significant partnerships with major pharmaceutical companies like Novartis, validating its QuEEN platform. These factors contribute to investor confidence and enhance the market potential of Monte Rosa's therapeutic candidates.
GLUE - Phase 2 Degrader Pipeline And Long Cash Runway Will Support Future Clinical Upside
Monte Rosa Therapeutics (GLUE) is positioned for future growth with multiple Phase 2 trials for its molecular glue degrader platform in cardiovascular, immunology, and oncology, supported by a strong cash runway extending into 2029. Key programs like MRT-8102 are entering advanced trials for conditions such as coronary artery disease and gout, with potential for significant clinical and financial upside. Analysts view the company as undervalued, projecting substantial revenue growth but also highlighting risks related to trial delays and financial performance deviations from expectations.
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company focused on developing novel small molecule precision medicines, including molecular glue degraders (MGDs) for various diseases like cancer, autoimmune, and inflammatory conditions. The article provides detailed financial data, stock performance metrics, analyst ratings, and company overview, indicating a current stock price of $11.26 with a target estimate of $28.00. The company's pipeline includes MRT-2359, MRT-6160, and MRT-8102, and it has strategic collaborations with F. Hoffmann-La Roche Ltd. and Novartis.
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Monte Rosa Therapeutics announced it will host a conference call and webcast on October 1st to present results from its GFORCE-1 Phase 1 study of MRT-8102. The presentation will cover safety and activity data for MRT-8102 in subjects with elevated cardiovascular disease risk, highlighting its potential to modulate pathogenic drivers of atherosclerotic cardiovascular disease. The webcast will be available on Monte Rosa's website.
Monte Rosa to Present MRT-8102 Phase 1 Data Oct. 1 | GLUE Stock News
Monte Rosa Therapeutics (GLUE) announced it will present results from its MRT-8102 GFORCE-1 Phase 1 study via webcast on October 1, 2026, at 8:00 a.m. ET. The presentation will detail safety and activity data for MRT-8102 across various dose levels after four weeks of treatment in subjects with elevated cardiovascular disease risk, including its effects on atherosclerotic cardiovascular disease drivers. This comes after previous interim results showed reductions in hsCRP and NEK7 degradation, and the stock saw a significant positive movement after the news.
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE
Bank of America Corp DE has acquired 254,561 shares of Monte Rosa Therapeutics (NASDAQ:GLUE) worth approximately $6.16 million, representing a 0.30% stake in the company. Other institutional investors have also increased their holdings, with institutional investors and hedge funds now owning nearly 80% of the company. Despite Monte Rosa Therapeutics missing its Q2 earnings and revenue estimates, analysts maintain a "Moderate Buy" rating with an average price target of $28.50.
(GLUE) Movement Within Algorithmic Entry Frameworks
This article from Stock Traders Daily's Quantitative Research Desk analyzes Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) using algorithmic entry frameworks. It highlights weak near- and mid-term sentiment, posing a challenge to a potentially strong long-term outlook. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels based on AI-generated signals and multi-timeframe analysis.
What Monte Rosa Therapeutics (GLUE)'s Phase 2 Trial Start Means For Shareholders
Monte Rosa Therapeutics received a US$50 million milestone payment from Novartis as its VAV1-directed degrader MRT-6160 entered a Phase 2a/b trial for Sjögren's disease. This collaboration with Novartis provides near-term funding relief and shifts development costs, making MRT-6160 a key economic driver for Monte Rosa, despite the company's current unprofitability and high P/S ratio. The focus now shifts to trial progress and potential new partnerships as the company manages its investment narrative.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Moderate Buy" by Analysts
Analysts have assigned Monte Rosa Therapeutics (NASDAQ:GLUE) an average rating of "Moderate Buy," with a consensus 12-month price target of $28.50. Despite this, the company recently reported a wider-than-expected quarterly loss and missed revenue estimates. The stock opened significantly below analyst targets, and institutional investors hold a substantial portion of the company, while insiders sold a notable number of shares in the last quarter.
Can Monte Rosa Therapeutics (NASDAQ:GLUE) Rewrite Its Story?
Monte Rosa Therapeutics (NASDAQ:GLUE) is a clinical-stage biotechnology company focused on developing small-molecule medicines using its proprietary Tunable Molecular Glue platform for targeted protein degradation. The company is drawing attention due to its innovative scientific approach, ongoing clinical development, and recent financial figures which showed wider-than-expected losses and lower sales, highlighting the financial demands of clinical-stage biotech. Its market narrative is influenced by pipeline progress, institutional ownership, and its unique technology aimed at eliminating disease-causing proteins.
What’s Behind Monte Rosa Therapeutics (NASDAQ:GLUE) Latest Slide?
Monte Rosa Therapeutics (NASDAQ:GLUE) has experienced a market slide, putting renewed focus on its clinical-stage biotechnology business. The company specializes in molecular glue technology to selectively remove disease-causing proteins, a distinct approach in drug development. Recent weaker quarterly figures and ongoing clinical development are contributing factors to the pressure on GLUE, highlighting the significant financial resources required for its scientific platform and pipeline advancement.
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 6% - What's Next?
Monte Rosa Therapeutics (NASDAQ:GLUE) experienced a 6% drop in its stock price, trading at $13.07, with a significant decrease in trading volume. This decline follows the company missing its quarterly earnings and revenue expectations. Despite the negative performance and insider stock sales, analysts generally maintain a "Moderate Buy" rating with an average price target of $28.50.
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
Novartis has paid Monte Rosa Therapeutics a $50 million milestone payment after dosing the first patient in a Phase 2 trial for MRT-6160, a VAV1-targeted drug for Sjögren's disease. This is part of a larger deal potentially worth up to $2.1 billion. While Monte Rosa is advancing other pipeline candidates and has sufficient cash into 2029, the company faces growing losses and mixed investor sentiment regarding its future trajectory.
Opaleye Management Inc. Acquires Shares of 745,000 Monte Rosa Therapeutics, Inc. $GLUE
Opaleye Management Inc. has acquired a new stake of 745,000 shares in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), valued at approximately $18 million, making it their 17th largest holding. This acquisition gives Opaleye Management a 0.87% ownership in the company, which is 79.96% institutionally owned. Despite recent insider selling and weaker-than-expected quarterly results, analysts maintain a "Moderate Buy" rating with a consensus price target of $28.50.
Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Wellington Management Group LLP significantly increased its stake in Monte Rosa Therapeutics (NASDAQ:GLUE) by 61.1% in the second quarter, acquiring an additional 78,635 shares to reach a total of 207,427 shares valued at $5.02 million. This move is part of broader institutional interest, with such investors now owning nearly 80% of the company, despite recent insider selling and Monte Rosa Therapeutics reporting a wider-than-expected quarterly loss and lower revenue. Analysts maintain a "Moderate Buy" rating with a consensus price target of $28.50.
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
LifeSci Capital has reiterated its Buy rating on Monte Rosa Therapeutics (GLUE.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush
Wedbush has reaffirmed its "Outperform" rating for Monte Rosa Therapeutics (NASDAQ:GLUE) with a $27 price target, suggesting a significant upside. Despite a generally positive analyst consensus of "Moderate Buy" and an average target of $28.50, the company recently missed quarterly earnings and revenue estimates, and insiders have sold a substantial number of shares. Institutional investors and hedge funds have shown varying activity, with some increasing and others initiating positions.
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial
Monte Rosa Therapeutics (GLUE) will receive a $50 million milestone payment as its collaborator Novartis initiates a Phase 2 clinical study for MRT-6160 (DDY391), a VAV1-directed molecular glue degrader, in patients with Sjögren’s disease. This study is the first of several expected, with Monte Rosa potentially eligible for up to $2.1 billion in additional milestones and a 30% share of U.S. profits for MRT-6160. The Phase 2a/b trial will assess the efficacy, safety, and tolerability of MRT-6160 over 52 weeks and support Phase 3 dose selection.
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Monte Rosa Therapeutics announced that its collaborator Novartis has initiated a Phase 2 clinical study for the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in patients with Sjögren's disease. This milestone triggers a $50 million payment to Monte Rosa from Novartis, as part of a global exclusive development and commercialization license agreement. The study aims to evaluate the efficacy, safety, and tolerability of MRT-6160, which has shown promising preclinical and Phase 1 results, in addressing this autoimmune disease with high unmet medical need.
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160
Monte Rosa Therapeutics announced a milestone achievement as its collaborator Novartis initiated a Phase 2 clinical study for the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in patients with Sjögren's disease. Monte Rosa will receive a $50 million milestone payment from Novartis due to the first patient visit in the study. The company is eligible for up to $2.1 billion in additional development, regulatory, and sales milestones under their exclusive development and commercialization license agreement.
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE
Bank of New York Mellon Corp has acquired a new position in Monte Rosa Therapeutics, purchasing 222,521 shares valued at approximately $5.4 million, making them a significant institutional investor. This comes as Monte Rosa Therapeutics missed its latest quarterly earnings expectations, reporting an adjusted loss of $0.43 per share against an estimate of $0.38, and revenue of $8.97 million against a forecast of $12.91 million. Despite recent insider selling and a 3.8% dip in share price, analysts maintain a "Moderate Buy" rating with an average price target of $28.50.
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP
Braidwell LP reduced its stake in Monte Rosa Therapeutics (NASDAQ:GLUE) by 23.5% in Q2 2026, selling 755,012 shares but still holding 2.45 million shares valued at $59.3 million. Despite this, institutional ownership remains high at nearly 80%, with major firms like BlackRock, State Street, and AQR Capital Management increasing their holdings. GLUE holds a "Moderate Buy" consensus rating with a $28.50 price target, though the company recently missed earnings and revenue estimates.
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE
The Manufacturers Life Insurance Company has acquired 191,877 shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a new position valued at approximately $4.64 million, representing about 0.22% of the company. Despite this institutional interest, Monte Rosa Therapeutics recently missed quarterly earnings expectations, reporting an adjusted loss of $0.43 per share and $8.97 million in revenue. Analysts, however, maintain a "Moderate Buy" consensus rating with an average price target of $28.50, even after some recent target reductions.
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE
Montanova Capital LLC reduced its stake in Monte Rosa Therapeutics (NASDAQ:GLUE) by 16% in the second quarter, selling 677,270 shares but still retaining 3.55 million shares valued at approximately $85.9 million. Despite this sale and a recent earnings miss, analysts maintain a "Moderate Buy" consensus rating with an average price target of $28.50. The company, focused on AI-driven drug discovery, reported a quarterly loss and missed revenue estimates, with its stock opening significantly below its 52-week high.
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE
Empowered Funds LLC recently acquired 329,266 shares of Monte Rosa Therapeutics, valued at approximately $7.97 million, representing about 0.39% of the company's stock. This purchase comes as Monte Rosa Therapeutics faces a 6.6% stock decline, trading at $13.38, well below its 12-month high. Despite missing quarterly earnings and revenue expectations, analysts maintain a "Moderate Buy" rating with a consensus target price of $28.50.
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE
Deutsche Bank AG has invested $1.82 million in Monte Rosa Therapeutics, acquiring 75,061 shares, which constitutes a 0.09% stake in the company. Despite Monte Rosa reporting weaker-than-expected quarterly results and recent insider share sales, analysts maintain a "Moderate Buy" rating with a consensus price target of $28.50. The institutional ownership of GLUE stands at 79.96%, reflecting significant interest from other investment firms as well.
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE
Nantahala Capital Management LLC has acquired 651,993 shares of Monte Rosa Therapeutics (NASDAQ:GLUE), a stake worth approximately $15.8 million, representing 0.76% of the company. Despite this significant institutional investment, the company recently reported an adjusted loss per share of $0.43 against an estimated $0.38 and missed revenue expectations. Monte Rosa Therapeutics shares opened down 6.6% at $13.38, while analysts maintain a "Moderate Buy" consensus with an average price target of $28.50.
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics has dosed the first patient in its MODeFIRe-1 Phase 2 study, evaluating MRT-2359 alongside apalutamide for metastatic castration-resistant prostate cancer with AR mutations. This study builds on promising results from a prior Phase 1/2 trial, where MRT-2359 combined with enzalutamide showed significant PSA and RECIST responses in a similar patient group. The company aims to further confirm clinical activity in this population, potentially advancing MRT-2359 towards registrational development.
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC
Boone Capital Management LLC has acquired 615,287 shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), valued at approximately $14.9 million, making it the 11th largest position in Boone Capital's portfolio. Despite this significant institutional investment and a "Moderate Buy" consensus rating from analysts, Monte Rosa Therapeutics reported a quarterly loss and revenue miss, alongside recent insider share sales. The company, which focuses on drug discovery using single-cell genomics and AI, has seen its stock fluctuate with a 1-year low of $4.60 and a high of $25.77.
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE
Bank of America Corp DE significantly increased its stake in Monte Rosa Therapeutics (NASDAQ:GLUE) by 73.3% in the first quarter, now holding 387,542 shares valued at approximately $6.4 million. Despite institutional interest, the stock traded down 1.2% to $14.38 and missed analyst expectations for EPS and revenue in its latest quarterly report. Analysts maintain a "Moderate Buy" consensus with an average price target of $28.50, though company insiders have sold approximately $1.73 million worth of shares recently.
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE
ADAR1 Capital Management LLC has acquired 216,752 shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) for approximately $5.25 million, marking a new stake in the company. Institutional investors collectively own nearly 80% of GLUE, which recently reported a quarterly loss missing analyst estimates and announced the initiation of a Phase 2 prostate cancer trial for its lead program. Analysts maintain a consensus "Moderate Buy" rating with a price target of $28.50, despite recent insider share sales.
Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive
Monte Rosa Therapeutics (GLUE) recently initiated its MODeFIRe-1 Phase 2 trial for MRT-2359, which helped maintain investor interest despite recent stock price declines. While the company shows long-term gains, its current price-to-sales ratio of 43.2x suggests it is overvalued compared to peers and the broader biotech industry. Investors are cautioned to weigh the clinical progress against significant risks like potential trial setbacks and ongoing financial losses.
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 7.4% Higher on Analyst Upgrade
Monte Rosa Therapeutics (NASDAQ:GLUE) saw its shares rise 7.4% after TD Cowen upgraded the stock to a Strong Buy rating. Despite recent target price reductions from other firms and a missed earnings report, the company maintains a "Moderate Buy" consensus rating with an average target price of $28.50. Insider transactions show some selling activity, while institutional investors have adjusted their stakes in the company.
Guggenheim Reaffirms "Buy" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)
Guggenheim has reiterated its "Buy" rating for Monte Rosa Therapeutics (NASDAQ:GLUE), setting a $28 price target, which suggests a significant upside. Despite this positive outlook, the company recently reported an adjusted loss of $0.43 per share and revenue of $8.97 million, both falling short of analyst expectations. Institutional investors hold a substantial portion of the company's stock, while insiders have sold shares worth approximately $1.77 million in the last quarter.
Monte Rosa starts Phase 2 MRT-2359 prostate cancer trial
Monte Rosa Therapeutics has initiated a Phase 2 trial (MODeFIRe-1) for its investigational molecular glue degrader MRT-2359 combined with apalutamide, targeting metastatic castration-resistant prostate cancer with AR mutations. The study aims to enroll up to 25 patients and will evaluate treatment responses and safety, building on previous data showing positive PSA responses in AR-mutant patients. Updated data from an earlier expansion arm is anticipated by year-end.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $28.50, despite recent reductions in price targets by some analysts. The company's stock opened at $14.30, significantly below its 52-week high, after reporting quarterly revenues and EPS that missed analyst expectations. Insider sales of 81,778 shares worth $1.77 million were noted, while institutional investors, including a new position by BlackRock, hold nearly 80% of the company's shares.
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics has dosed the first patient in its MODeFIRe-1 Phase 2 study for MRT-2359. This study evaluates MRT-2359 in combination with apalutamide for patients with AR mutation-positive metastatic castration-resistant prostate cancer (mCRPC). The trial builds upon encouraging previous Phase 1/2 data and aims to assess the efficacy and safety of the combination therapy.
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics announced the dosing of the first patient in its MODeFIRe-1 Phase 2 study for MRT-2359, a molecular glue degrader, in combination with apalutamide for metastatic castration-resistant prostate cancer patients with AR mutations. This study builds on positive data from a previous Phase 1/2 trial, where MRT-2359 in combination with enzalutamide showed encouraging results in a similar patient population. The company expects to release updated data from the initial Phase 1/2 study by the end of the year and hopes to advance MRT-2359 into registrational development.
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics has dosed its first patient in the MODeFIRe-1 Phase 2 study, evaluating MRT-2359 in combination with apalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) with AR mutations. This study follows encouraging Phase 1/2 data for MRT-2359 with enzalutamide, showing promising PSA and RECIST responses in heavily pretreated mCRPC patients with AR mutations. The company aims to confirm clinical activity in this population, potentially leading to registrational development and expanded treatment options for AR-driven prostate cancer.
